Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis
Abstract Spondyloarthritis (SpA) is a group of chronic inflammatory systemic diseases characterized by axial and/or peripheral joints inflammation, as well as extra-articular manifestations. Over some decades, nonsteroidal anti-inflammatory drugs (NSAIDs) have been the basis for the pharmacological treatment of patients with axial spondyloarthritis (axSpA). However, the emergence of the immunobiologic agents brought up the discussion about the role of NSAIDs in the management of these patients. The objective of this guideline is to provide recommendations for the use of NSAIDs for the treatment of axSpA. A panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis of randomized clinical trials for 15 predefined questions. The Grading of Recommendations, Assessment, Development and Evaluation methodology to assess the quality of evidence and formulate recommendations were used, and at least 70% agreement of the voting panel was needed. Fourteen recommendations for the use of NSAIDs in the treatment of patients with axSpA were elaborated. The purpose of these recommendations is to support clinicians’ decision making, without taking out his/her autonomy when prescribing for an individual patient..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Advances in rheumatology - 61(2021), 1 vom: 19. Jan. |
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Ankylosing spondylitis |
|---|
| Anmerkungen: |
© The Author(s) 2021 |
|---|
| doi: |
10.1186/s42358-020-00160-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2122872993 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2122872993 | ||
| 003 | DE-627 | ||
| 005 | 20230505070047.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230505s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s42358-020-00160-6 |2 doi | |
| 035 | |a (DE-627)OLC2122872993 | ||
| 035 | |a (DE-He213)s42358-020-00160-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a da Cruz Lage, Ricardo |e verfasserin |0 (orcid)0000-0001-6220-8585 |4 aut | |
| 245 | 1 | 0 | |a Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2021 | ||
| 520 | |a Abstract Spondyloarthritis (SpA) is a group of chronic inflammatory systemic diseases characterized by axial and/or peripheral joints inflammation, as well as extra-articular manifestations. Over some decades, nonsteroidal anti-inflammatory drugs (NSAIDs) have been the basis for the pharmacological treatment of patients with axial spondyloarthritis (axSpA). However, the emergence of the immunobiologic agents brought up the discussion about the role of NSAIDs in the management of these patients. The objective of this guideline is to provide recommendations for the use of NSAIDs for the treatment of axSpA. A panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis of randomized clinical trials for 15 predefined questions. The Grading of Recommendations, Assessment, Development and Evaluation methodology to assess the quality of evidence and formulate recommendations were used, and at least 70% agreement of the voting panel was needed. Fourteen recommendations for the use of NSAIDs in the treatment of patients with axSpA were elaborated. The purpose of these recommendations is to support clinicians’ decision making, without taking out his/her autonomy when prescribing for an individual patient. | ||
| 650 | 4 | |a Spondyloarthritis | |
| 650 | 4 | |a Ankylosing spondylitis | |
| 650 | 4 | |a Nonsteroidal anti-inflammatory drugs | |
| 650 | 4 | |a Systematic review | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Guidelines | |
| 700 | 1 | |a Marques, Claudia Diniz Lopes |4 aut | |
| 700 | 1 | |a Oliveira, Thauana Luiza |4 aut | |
| 700 | 1 | |a Resende, Gustavo Gomes |4 aut | |
| 700 | 1 | |a Kohem, Charles Lubianca |4 aut | |
| 700 | 1 | |a Saad, Carla Gonçalves |4 aut | |
| 700 | 1 | |a Ximenes, Antônio Carlos |4 aut | |
| 700 | 1 | |a Gonçalves, Célio Roberto |4 aut | |
| 700 | 1 | |a Bianchi, Washington Alves |4 aut | |
| 700 | 1 | |a de Souza Meirelles, Eduardo |4 aut | |
| 700 | 1 | |a Keiserman, Mauro Waldemar |4 aut | |
| 700 | 1 | |a Chiereghin, Adriano |4 aut | |
| 700 | 1 | |a Campanholo, Cristiano Barbosa |4 aut | |
| 700 | 1 | |a Lyrio, André Marun |4 aut | |
| 700 | 1 | |a Schainberg, Cláudia Goldenstein |4 aut | |
| 700 | 1 | |a Pieruccetti, Lenise Brandao |4 aut | |
| 700 | 1 | |a Yazbek, Michel Alexandre |4 aut | |
| 700 | 1 | |a Palominos, Penelope Esther |4 aut | |
| 700 | 1 | |a Goncalves, Rafaela Silva Guimarães |4 aut | |
| 700 | 1 | |a Assad, Rodrigo Luppino |4 aut | |
| 700 | 1 | |a Bonfiglioli, Rubens |4 aut | |
| 700 | 1 | |a Lima, Sônia Maria Alvarenga Anti Loduca |4 aut | |
| 700 | 1 | |a Carneiro, Sueli |4 aut | |
| 700 | 1 | |a Azevedo, Valderílio Feijó |4 aut | |
| 700 | 1 | |a Albuquerque, Cleandro Pires |4 aut | |
| 700 | 1 | |a Bernardo, Wanderley Marques |4 aut | |
| 700 | 1 | |a Sampaio-Barros, Percival Degrava |4 aut | |
| 700 | 1 | |a de Medeiros Pinheiro, Marcelo |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in rheumatology |d BioMed Central, 2018 |g 61(2021), 1 vom: 19. Jan. |h Online-Ressource |w (DE-627)1028897588 |w (DE-600)2939120-9 |w (DE-576)510014682 |x 2523-3106 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2021 |g number:1 |g day:19 |g month:01 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s42358-020-00160-6 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2021 |e 1 |b 19 |c 01 | ||